Year: 2014
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Reduced cerebrospinal fluid (CSF) β-amyloid42 (Aβ42) and increased florbetapir positron emission tomography (PET) uptake reflects brain Aβ accumulation. These biomarkers are correlated with each other and altered in Alzheimer's disease (AD), but no study has directly compared their diagnostic performance. METHODS: We examined healthy controls (CN, N = 169) versus AD dementia patients (N = 118), and stable (sMCI; no dementia, followed up for at least 2 years, N = 165) versus progressive MCI (pMCI; conversion to AD dementia, N = 59). All subjects had florbetapir PET (global and regional; temporal, frontal, parietal, and cingulate) and CSF Aβ42 measurements at baseline. We compared area under the curve (AUC), sensitivity, and specificity (testing a priori and optimized cutoffs). Clinical diagnosis was the reference standard. RESULTS: CSF Aβ42 and (global or regional) PET florbetapir did not differ in AUC (CN vs. AD, CSF 84.4%; global PET 86.9%; difference [95% confidence interval] -6.7 to 1.5). CSF Aβ42 and global PET florbetapir did not differ in sensitivity, but PET had greater specificity than CSF in most comparisons. Sixteen CN progressed to MCI and AD (six Aβ negative, seven Aβ positive, and three PET positive but CSF negative). INTERPRETATION: The overall diagnostic accuracies of CSF Aβ42 and PET florbetapir were similar, but PET had greater specificity. This was because some CN and sMCI subjects appear pathological using CSF but not using PET, suggesting that low CSF Aβ42 not always translates to cognitive decline or brain Aβ accumulation. Other factors, including costs and side effects, may also be considered when determining the optimal modality for different applications.
DOI: 10.1002/acn3.81
Authors: Niklas Mattsson, Philip S. Insel, Susan Landau, William Jagust, Michael Donohue, Leslie M. Shaw, John Q. Trojanowski, Henrik Zetterberg, Kaj Blennow, Michael Weiner, the Alzheimer's Disease Neuroimaging Initiative
Institutions: San Francisco VA Medical Center, University of California, San Francisco, University of Gothenburg, University of California, Berkeley, University of California San Diego, University of Pennsylvania, National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, University College London, Alzheimer’s Disease Neuroimaging Initiative
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,100
Funders: Foundation for the National Institutes of Health, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Novartis, Roche, Medpace, Synarc, Alzheimer's Disease Neuroimaging Initiative, Northern California Institute for Research and Education, Elan, Eisai, Vetenskapsrådet, Sahlgrenska Universitetssjukhuset, National Institutes of Health, U.S. Food and Drug Administration, Genentech, University of California, San Diego, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
Awards: UC Davis Alzheimer's Disease Core Center, G2835601961, G29951154, G3146424788, G3218891203, G3870774570, G3966393351, "MR Morphometrics and Cognitive Decline Rate in Large-Scale Aging Studies", G4196769506, G4401988282, Alzheimer's Disease Neuroimaging Initiative, G9000074849, G9000087106, G9000122335, G920654007
OpenAlex ID: W1964472291
